AU2019297321B2 - Novel immunodulating small molecules - Google Patents

Novel immunodulating small molecules Download PDF

Info

Publication number
AU2019297321B2
AU2019297321B2 AU2019297321A AU2019297321A AU2019297321B2 AU 2019297321 B2 AU2019297321 B2 AU 2019297321B2 AU 2019297321 A AU2019297321 A AU 2019297321A AU 2019297321 A AU2019297321 A AU 2019297321A AU 2019297321 B2 AU2019297321 B2 AU 2019297321B2
Authority
AU
Australia
Prior art keywords
nhac
compound
tlr4
formulated
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019297321A
Other languages
English (en)
Other versions
AU2019297321A1 (en
Inventor
Suchismita ACHARYA
Beamon Agarwal
Pragnya DAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ayuvis Research Inc
Original Assignee
Ayuvis Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayuvis Research Inc filed Critical Ayuvis Research Inc
Publication of AU2019297321A1 publication Critical patent/AU2019297321A1/en
Application granted granted Critical
Publication of AU2019297321B2 publication Critical patent/AU2019297321B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2019297321A 2018-07-02 2019-07-02 Novel immunodulating small molecules Active AU2019297321B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693023P 2018-07-02 2018-07-02
US62/693,023 2018-07-02
PCT/US2019/040313 WO2020010090A1 (en) 2018-07-02 2019-07-02 Novel immunodulating small molecules
US16/460,211 US11364253B2 (en) 2018-07-02 2019-07-02 Immunodulating small molecules
US16/460,211 2019-07-02

Publications (2)

Publication Number Publication Date
AU2019297321A1 AU2019297321A1 (en) 2021-02-18
AU2019297321B2 true AU2019297321B2 (en) 2022-02-03

Family

ID=69060166

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019297321A Active AU2019297321B2 (en) 2018-07-02 2019-07-02 Novel immunodulating small molecules

Country Status (8)

Country Link
US (1) US11364253B2 (https=)
JP (2) JP7728560B2 (https=)
KR (1) KR20210027381A (https=)
AU (1) AU2019297321B2 (https=)
BR (1) BR112020026989A2 (https=)
CA (1) CA3103503A1 (https=)
MX (1) MX2020014087A (https=)
WO (1) WO2020010090A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220143059A1 (en) * 2016-03-30 2022-05-12 Ayuvis Research, Inc. Compositions and therapeutic methods
US12594286B2 (en) 2018-07-02 2026-04-07 Ayuvis Research, Inc. Immunodulating small molecules
WO2022169855A1 (en) * 2021-02-04 2022-08-11 Ayuvis Research, Inc. Chitin analogs for the treatment of kidney diseases
US12440471B2 (en) * 2021-07-30 2025-10-14 Ayuvis Research, Inc. Compositions and methods for the treatment of bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension
WO2023086877A1 (en) * 2021-11-12 2023-05-19 Ayuvis Research, Inc. Novel compositions and therapeutic methods
EP4531867A1 (en) * 2022-05-25 2025-04-09 Ayuvis Research, Inc. Novel immunodulating small molecules
WO2024220628A1 (en) * 2023-04-18 2024-10-24 The Regents Of The University Of Colorado, A Body Corporate Target for combatting the foreign body response to implantable biomaterials
US20250332183A1 (en) * 2024-04-30 2025-10-30 Ayuvis Research, Inc. Compositions and methods for the stimulation of intermediate macrophages and treatments therewith

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404365A (en) * 1981-12-28 1983-09-13 American Cyanamid Company Modulators of the complement system

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US4621075A (en) 1984-11-28 1986-11-04 The Procter & Gamble Company Gel-form topical antibiotic compositions
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
EP0273512B1 (en) 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
CN1053193C (zh) * 1993-11-15 2000-06-07 吴羽化学工业株式会社 七叶亭衍生物和其制造方法与用途及其医药组合物
AU7484198A (en) 1997-05-12 1998-12-08 Sage Pharmaceuticals, Inc. Topical spray for burn treatment and anti-infection
JP2004505925A (ja) * 2000-08-10 2004-02-26 オーシャン、ニュートリッション、カナダ、リミテッド 免疫調節特性を示すクロレラ調製物
US20050255048A1 (en) 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
WO2008054892A2 (en) * 2006-06-16 2008-05-08 Florida Atlantic University Chitin micro-particles as an adjuvant
WO2016077567A1 (en) * 2014-11-12 2016-05-19 Tumorend, Llc Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration
JP2019513137A (ja) 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404365A (en) * 1981-12-28 1983-09-13 American Cyanamid Company Modulators of the complement system

Also Published As

Publication number Publication date
BR112020026989A2 (pt) 2021-03-30
US20200022995A1 (en) 2020-01-23
WO2020010090A1 (en) 2020-01-09
KR20210027381A (ko) 2021-03-10
JP2021535080A (ja) 2021-12-16
JP7728560B2 (ja) 2025-08-25
CA3103503A1 (en) 2020-01-09
US11364253B2 (en) 2022-06-21
AU2019297321A1 (en) 2021-02-18
MX2020014087A (es) 2021-04-12
JP2023109826A (ja) 2023-08-08

Similar Documents

Publication Publication Date Title
AU2019297321B2 (en) Novel immunodulating small molecules
Guo et al. Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy
AU2025205307A1 (en) Novel compositions and therapeutic methods
ES2389080T3 (es) Fármaco que presenta un ligando de células reguladoras contenido en el liposoma
WO2009099650A2 (en) Treatment of bladder diseases with a tlr7 activator
EP3820512B1 (en) Immunomodulating compositions comprising oligosaccharide derivatives
JP2019533644A (ja) 薬物送達のための透過促進剤を有する組成物
US12594286B2 (en) Immunodulating small molecules
EP4531867A1 (en) Novel immunodulating small molecules
HK40042187B (en) Immunomodulating compositions comprising oligosaccharide derivatives
HK40042187A (en) Immunomodulating compositions comprising oligosaccharide derivatives
CA3201106A1 (en) Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics
KR102721070B1 (ko) Rsvf를 발현하는 엑소좀 및 이의 용도
US20220241306A1 (en) Chitin analogs for the treatment of kidney diseases
WO2024173723A2 (en) Use of crassocephalum rabens extract in inducing humoral immune response
US20220143059A1 (en) Compositions and therapeutic methods
EP3000471A1 (en) Novel immunostimulatory molecules
AU2022383860A1 (en) Novel compositions and therapeutic methods
Yakuboğulları Investigating immunomodulator mechanisms of Astragalus saponins
HK40004181B (en) Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)